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We determined the therapeutic efficacy of atractylenolide I (ATR), extracted from largehead
atractylodes rhizome, in managing gastric cancer cachexia (GCC), and interpreted
its probable pharmacological mechanism via investigating tumor necrosis factor alpha (TNF-a),
interleukin-1 (IL-1), interleukin-6 (IL-6) and proteolysis-inducing factor (PIF). This was a
randomized but not-blinded pilot. The study group (n¼11) received 1.32g per day of
atractylenolide I (ATR) and the control group (n¼11) received 3.6g per day of fish-oil-enriched
nutritional supplementation (FOE) for 7 weeks. Conservative therapy was similar in both groups.
Clinical [appetite, body weight, mid-arm muscle circumference (MAMC), Karnofsky performance
status (KPS) status], biomarker (TNF-a, IL-1, IL-6 and PIF) were evaluated in the basal state, at
the third and seventh weeks. To analyze changes of cytokines, an immumohistochemistry
technique was adopted. Base line characteristics were similar in both groups. Effects on MAMC
and body weight increase, TNF-a increase and IL-1 decreases of serum level were significant in
both groups (P50.05). ATR was significantly more effective than FOE in improving appetite and
KPS status, and decreasing PIF positive rate (P50.05). Slight nausea (3/11) and dry mouth (1/11)
were shown in intervention groups but did not interrupt treatment. These preliminary findings
suggest that ATR might be beneficial in alleviating symptoms, in modulating cytokine and in
inhibiting PIF proteolysis of gastric cancer cachexia. Further research using a randomized
controlled design is necessary to confirm these pilot study findings.
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Introduction
Cachexia, the most common manifestation of advanced
malignant diseases, is responsible for 22% of all cancer
patients’ deaths (1,2). Cachexia is characterized by
progressive weight loss and depletion of lean and fat
body mass (3), and is associated with shorter survival
period and reduced quality of life (4,5). Patients with
gastric cancer have a high incidence of cachexia.
Currently, an optimized treatment of cancer is the best
therapy of cachexia, however, no effective systemic
antineoplastic therapy has been found, and the toxicity
of conventional chemotherapy may do harm to a
patient’s nutritional status. Therefore, it is necessary to
find a simple, inexpensive and non-toxic compound to
improve appetite and ameliorate quality of life for
patients with advanced gastric malignancy.
In China, largehead atractylodes rhizome [family:
Compositae] has been used to ameliorate gastrointestinal
tract symptoms, such as anorexia for 2000 years.
Largehead atractylodes rhizome is used well clinically as
tonic. It has been applied clinically for recuperation after
surgery or chronic diseases with symptoms such as
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properly cited.exhaustion, fatigue, pale face, diarrhea, loss of appetite,
vomiting and anorexia, especially for the patients having
digestive disorder (6). Largehead atractylodes rhizome is
also used for the treatments of carcinoma (7). Modern
pharmacological researchers have confirmed that large-
head atractylodes rhizome is effective in promoting
gastrointestinal motility and intestinal secretion (8–10).
Atractylodes rhizome and especially constituents of it has
multiple pharmacological actions which are favorable for
treating cancer (11–13). Atractylenolide I (ATR), the
main bioactive chemical compound of largehead atracty-
lodes rhizome (14–16), has been reported to induce
apoptosis and bring about cytotoxicity of human
promyeloleukemic HL-60 cells (17). ATR and atractylon
were the major cytotoxic principle constituents of
atractylodes rhizome on leukemia cell lines, but atracty-
lenolides II and III showed no significant inhibition
effects on tumor cell’s growth (15). Furthermore,
atractylenolide I has an anti-inflammatory effect (16).
All of the data above suggests that ATR might play a
useful role in the palliation of the cancer cachexia
syndrome. However, currently available data does not
show whether ATR is effective in managing cancer
cachexia, and whether the mechanism also needs to be
elucidated. It is the aim of this study to document the
effects of largehead atractylodes rhizome treatment in
alleviating symptoms via modulating cytokine and in
inhibiting of proteolysis-inducing factor (PIF) proteolysis
of gastric cancer cachexia.
Materials and Methods
Study Approval, Participant Criteria and Recruitment
Between November 2002 and May 2005 (31 months),
22 in-patients (13 men and 9 women) out of 62 gastric
cachexia cancer patients in the Traditional Chinese
Medicine department of the First Affiliated Hospital of
Xi’an Jiaotong University were recruited, and meet the
following eligibility criteria: (i) diagnosis of advanced
unresectable gastric cancer; (ii) diminished or absent
appetite; (iii) ability to take drugs orally; (iv) life
expectancy 42 months and (v) no indication for further
chemo or radiotherapy. Patients with active infection,
severe heart, renal, or hepatic disease, primary or
metastasis brain tumor, diabetes mellitus and those
receiving nutritional support were excluded. Patient
characteristics at baseline are outlined in Table 1.
No differences of baseline variables were found. Eleven
healthy people (seven men/four women) between the ages
of 45 and 75 years old (mean 59.5 years) were selected for
the healthy control group. Healthy volunteers were
recruited through placard in our hospital and net-
work advertisements run for a period of 1 month.
We conducted a physical examination to rule out
underlying pathology. All subjects gave their informed
consent. The ethics committee of Xi’an Jiaotong
University approved this study.
Study Design
We randomly divided 22 patients into two groups, and
each group had 11 patients. First, each group had a
separate randomization schedule. After recruiting five
patients of each group, we planned to recruit about an
equal number, age and state of an illness of participants
in the two groups by adaptive randomization method.
The control and treated herb was hid separately in a code
box with the same appearance. After each patient got his/
her randomized code from statistician, he/she came to the
pharmacy to get the certain drug of his/her code. All of
the participants completed the study after randomization.
It was clear for both the patients and the curer which
patient belonged to which treatment arm. Each patient
belonging to the fish-oil-enriched nutritional supplemen-
tation group (briefed as FOE) received eight gelatine
capsules of fish oil (EPAþDHA315mg) twice a day.
Each capsule contained 0.45g of fish oil. The second
group, briefed as ATR, received 6ml (containing
atractylenolide I 0.11gml
 1) twice a day, half an hour
after meals. The total duration of the study was 7 weeks,
which was divided into two treatment phases. Each
treatment phase contained 3 weeks of treatment and
1 week of rest. Patients received supportive care such as
non-opiate analgesic, antiemetics and laxatives during
therapy.
Outcome Measures
Study endpoints assessed and analyzed for each of
the participants consisted of both objective and
subjective measures. Primary outcome measures consisted
Table 1. Patients’ characteristics at baseline
FOE ATR
Age (years) 56(49–75 years) 58(45–75 years)
Stage (n)
IIIB 3 2
IV 8 9
Karnofsky performance scale (n)
90–100 0 0
70–80 2 2
50–60 7 8
30–40 2 1
Rate of body weight loss (kg)  0.10 to  0.07  0.12 to  0.10
Proteolysis-inducing
factor positive (n)
9 (81.8%) 10 (90.9%)
Rate of body weight loss: (LWW HSW)/HSW. HSW: Historical
stable weight; LWW: last week body weight.
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including the state/trait appetite scale and the perfor-
mance status (Karnofsky) score. Secondary objective
measures included body weight, mid-arm muscle circum-
ference (MAMC) serum level of tumor necrosis factor
alpha (TNF-a), interleukin-1 (IL-1), and interleukin-6
(IL-6), and PIF of urine sample. Aspartate transaminase
(AST), alanine transaminase (ALT) and urinary creati-
nine were assessed each week for patient safety and the
potential for liver or kidney toxicity. All outcome
measures were obtained at baseline, the third week and
seventh week by the same researcher who was blind to
group assignment.
Assessing Changes in Clinical Parameters
To evaluate patients’ appetite status, an Appetite Visual
Analogue Scale (VAS) was constructed. This is a 10-point
scale ranging from 0 (no appetite) to 10 (normal appetite)
(18). Each patient did self-report measures with instruc-
tions, and was asked to return the assessments in an
enclosed self-addressed envelope at the end of the study.
We determined the rate of change of patients’
Karnofsky performance status (RCKPS) and appetite
scale (RCA) as a surrogate to assess symptom relief.
We also calculated the rate of body-weight loss (RBWL)
and rate of change of mid-arm muscle circumference
(RCMAMC), and assessed the difference between the
two therapies.
Rate of change of clinical parameters ð%Þ
¼
post-treatment
pre-treatment
  1
Biochemical Analysis
Eleven healthy individuals’ (seven men/four women)
plasma sample were used as control values for cytokines.
Blood samples were immediately centrifuged at 3800 g
at 4 C for 10min. The supernatant was then discarded
and stored at  70 C. Analysis of the cytokines was
conducted by a radio immunoassay technique using
kits from Company of Fu-ri Biological Engineer
(Beijing, China).
Purification of PIF from the Urine of Patients and
Western Blot Analysis for PIF
24-h urine was treated with ammonium sulfate (80%
saturation) and stored overnight at 4 C. After two
rounds of 1h centrifuge, the supernatant was removed.
Samples of precipitate (5–10mg) were resolved on 12%
sodium dodecylsulphate, polyacrylamide gels (SDS/
PAGE). They were transferred to 0.45mm nitrocellulose
membranes, which were blocked with 5% Marvell in
Tris-buffered saline, pH 7.5, at 4 C overnight. 1:1000
dilution of PIF-specific antibodies and 1:1500 dilution of
anti-rat IgG conjugated with horseradish peroxidase were
incubated for 45min at room temperature, and develop-
ment was visualized by enhanced chemiluminescences.
The resulting bands were compared to pre-stained
molecular weight standards, which were run simulta-
neously to verify the appropriate molecular weight.
Plant Material and Preparation of Atractylenolide I
Largehead atractylodes rhizome was supplied and identi-
fied by the Taxonomist/Curator of the Department of
Chinese Herbs of the University of Shaanxi Traditional
Chinese Medicine. It was washed thoroughly with tap
water, dried, cut into small pieces, and then was extracted
by CO2 supercritical fluid extraction. Esquiterpenesolide
extracts of largehead atractylodes rhizome were prepared
with three stages as follows: flow rate of CO2
155–180kgh
 1, and first step: pressure 8 MPa, tempera-
ture 40 C, extraction time 2.5h; second step: 10MPa/
40 C, extraction time 2h; third step: 20MPa/40 C,
extraction time 2h. The volatile oil was only collected
at the third step, and the yield (%) of it was 2.42%. After
the extract was placed in a water bath for 72 days at
41 C, it was further separated by four stage molecular
distillation (MD) with separation process. Experiment
parameters of wiped film distillation were as follow: feed
temperature: 4 C; distillation temperature: 40–70 C;
pressure: 10–15Pa; rotating speed: 300–320rmin
 1, feed
rate: 3.0mlh
 1; and time 2h. The yield of distilled oil
was 28.6%. Chemical constituents of distilled oil were
analyzed with GC–MS. The extracted compounds were
separated on an HP-5MS capillary column
(30m 0.25mm 0.25mm). The column oven tempera-
ture was programmed as follows: 50 C (2min) to 120 C
at 5 Cmin
 1, then to 140 Ca t3  Cmin
 1, and main-
tained at 140 C for 5min, then to 280 Ca t1 0  Cmin
 1,
and maintained at 280 C for 30min. The injection
temperature and ion source temperature were 250 C
and 230 C. Helium was used as the carrier gas with a
flow rate of 1.0mlmin
 1. The ionizing energy was 70eV.
All data were obtained by collecting the full-scan mass
spectra within the scan range 40–350amu. The four
active compounds (atractylenolide I, atractylenolide II,
actylone, 3-b-hydroxyatxactylone) in the essential oil
were verified by their standards. The percentage of
ATR was calculated via area normalization method.
And the purity of it was 95.8%. ATR was dissolved with
tweenum-80 and was taken 6ml twice a day, half an hour
after meals.
Statistical Analysis
Data were expressed as point estimates, with 95%
confidence intervals. Analysis of serum levels IL-1, IL-6
eCAM 2008;5(3) 339and TNF-a and changes of clinical parameters were
performed using a two-tailed and paired t-test.
Comparisons of urine PIF between the two groups were
made using exact probabilities in a 2 2 table. P50.05
was considered statistically significant.
Results
Clinical Parameters
The Karnofsky Performance Score reflects the functional
ability of patients. As shown in Table 2 and Fig. 2, ATR
could improve appetite and KPS status, and was much
more efficient than FOE (P1,2,3,450.05). FOE and ATR
could both increase MAMC, and there was no statistical
difference between them. All patients were losing weight
before treatment (FOE: at a rate of  0.09kg; ATR: at a
rate of  0.11kg, Table 1), whereas after 3 weeks therapy
there was a median weight gain rate of 0.03kg (FOE) and
0.02kg (ATR). However, both ATR and FOE could not
completely reverse weight loss. After 7 weeks of treat-
ment, overall, 5 patients experienced weight gain, 10 had
stable weights, and 7 continued to lose weight but at a
reduced rate (FOE: median  0.09kg before supplemen-
tation vs  0.11kg after supplementation; ATR: median
 0.11kg before supplementation vs 0.00kg after
supplementation).
Serum Cytokine Levels
As shown in Tables 3 and 4 and Fig. 3, compared with
that of healthy people, serum IL-6 and IL-1 levels
increased and serum TNF-a levels decreased in gastric
patients (P50.05). After 3 weeks of treatment, only ATR
could statistically down-regulate the serum level of IL-1
towards normality. After 7 weeks of treatment, FOE
could statistically modulate serum levels of IL-1, IL-6
and TNF-a towards normality, whereas ATR had no
effect on IL-6.
Positive Rate of Urine PIF
As shown in Table 5 and Fig. 4, there was no significant
change of PIF positive rate after 3 weeks of treatment in
both groups. Both therapies decreased PIF positive rate,
Table 2. Rate of change of clinical parameters of GCC after 3 and 7
weeks of treatment with ATR or FOE (%)
3 weeks Assessment 7 weeks Assessment
FOE ATR FOE ATR
RCKPS 0.33–0.47 0.47–0.73*
P1 0.60–1.00 0.93–1.47*
P2
RCA 1.16–1.43 2.09–2.11*
P3 2.13–2.27 2.46–2.73*
P4
RBWL 0.02–0.04 0.01–0.03  0.02–0.00  0.01–0.01
RCMAMC 0.02–0.04 0.03–0.05 0.10–0.12 0.07–0.11
GCC: Gastric cancer cachexia; ATR: Atractylenolide I; FOE: Fish-
oil-enriched nutritional supplementation group; RCKPS: rate of change
of KPS status; RCA: rate of change of appetite scale; RBWL; rate of
body weight loss; RCMAMC: rate of change of mid-arm muscle
circumference. *P50.05 vs. fish-oil-enriched nutritional supplementa-
tion group. *P1¼0.01; *P2¼0.02; *P3¼0.00; *P4¼0.00.
Treatment group
Allocated to intervention (n=11)
Received allocated intervention (n=11)
Control group
Allocated to intervention (n=11)
Received allocated intervention (n=11)
Assessed for eligibility (n=62)
Excluded (n=40)
Did not meet inclusion criteria (n=13)
Refused to participate (n=26)
Other reasons (n=1)
Randomized (n=22)
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Figure 1. Study design and flow of subjects.
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Figure 2. Comparison of effects of FOE and ATR on gastric cancer cachectic patients in change of clinical parameters after 3 weeks and 7 weeks
treatment (A) rate of change of KPS status; (B) rate of change of appetite scale; (C) rate of body weight loss; (D) rate of change of mid-arm muscle
circumference (MAMC). The values represent the means and SEM of serum cytokine levels. *P50.05 when compared with FOE group.
Table 3. Change of Serum Cytokine levels of GCC after 3 weeks of treatment with ATR or FOE (pg ml
 1)
FOE (n¼11) ATR (n¼11) Healthy
Pre-treatment Post-treatment Pre-treatment Post-treatment
IL-1 5.39–22.31
yP1 5.87–13.93
yP2 10.44–15.96
yP3 2.61–7.59*
P12 4.59–6.61
IL-6 113.11–126.29
yP4 50.31–56.09
yP5 113.64–128.96
yP6 87.48–92.32
yP7 *
P13 17.14–23.06
TNF 15.11–21.29
yP8 24.75–29.05
yP9 10.99–22.01
yP10 35.97–42.83
yP11 *
P14 47.93–57.07
GCC: Gastric cancer cachexia; ATR: Atractylenolide I; FOE: Fish-oil-enriched nutritional supplementation group;
yP50.05 vs Healthy group;
P1¼0.05; P2¼0.01; P3¼0.00; P4¼0.00; P5¼0.00; P6¼0.00; P7¼0.00; P8¼0.00; P9¼0.00; P10¼0.00; P11¼0.00; *P50.05 vs fish-oil-enriched
nutritional supplementation group; P12¼0.03; P13¼0.00; P14¼0.00.
Table 4. Change of Serum Cytokine levels of GCC after 7 weeks of treatment with ATR or FOE (pg ml
 1)
FOE (n¼11) ATR (n¼11) Healthy
Pre-treatment Post-treatment Pre-treatment Post-treatment
IL-1 5.39–22.31
yP1 2.94–8.86 10.44–15.96
yP2 2.77–10.43 3.12–7.28
IL-6 113.11–126.29
yP3 14.25–26.35 113.64–128.96
yP4 34.36–45.24
yP5 *
P8 14.97–22.63
TNF 15.11–21.29
yP6 40.28–54.92 10.99–22.01
yP7 44.70–52.10 44.69–54.91
GCC: Gastric cancer cachexia; ATR: Atractylenolide I; FOE: Fish-oil-enriched nutritional supplementation group;
yP50.05 vs Healthy group,
P1¼0.05; P2¼0.00; P3¼0.00; P4¼0.00; P5¼0.00; P6¼0.00; P7¼0.00; *P50.05 vs fish-oil-enriched nutritional supplementation group, P8¼0.00.
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treatment at a statistically significant rate (P50.05).
Adverse Events
Almost all patients complained the bad taste of ATR.
The adverse events in treatment group that happened
at days 7–12 visit included slight nausea (3/11) and
dry mouth (1/11). But all of adverse events were
needed not to be cured. Almost all patients (9/11)
considered continuing use of ATR after termination of
the study.
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Figure 3. Comparison of effects of FOE and ATR on gastric cancer cachectic patients in change of serum cytokine levels after 3 weeks and 7 weeks
treatment (A) change of serum IL-1 levels; (B) change of serum IL-6 levels; (C) change of serum TNF-a levels. The values represent the means and
SEM of serum cytokine levels.
?P50.05 when compared with healthy group; *P50.05 when compared with FOE group.
Table 5. Positive rate of urine proteolysis-inducing factor of GCC after 3 and 7 weeks of treatment with ATR or FOE (n,%)
Pre-treatment 3 Weeks Assessment 7 Weeks Assessment
FOE ATR FOE ATR FOE ATR
Rate of PIF positive 9(48–98) 10(59–100) 7(31–89) 6(23–83) 6(23–83) 4(11–69)
y
Rate of PIF negative 2(2–52) 1(0–41) 4(11–69) 5(17–77) 5(17–77) 7(31–89)
GCC: Gastric cancer cachexia; ATR: atractylenolide I; FOE: Fish-oil-enriched nutritional supplementation group.
yP50.05 vs Pre-treatment.
54.5
90.9
54.5
63.6
81.8
36.0*
0 25 50 75 100
7 weeks
3 weeks
Pre-treatment
Positive rate of urine PIF (%)
FOE
ATR
Figure 4. Comparison of effects of FOE and ATR on gastric cancer
cachectic patients in change of positive rate of urine PIF after 3 weeks
and 7 weeks treatment. The bars represent the percent of urine positive
rate of PIF. *P50.05 when compared with pre-treatment.
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Gastric cancer cachexia is a common condition with a
dismaloutlook,aspharmacologicalandnutritionaltherapy
has led to rather disappointing results in the treatment of
cancer cachexia. For instance, although different TNF
synthesis inhibitors preserve the efficacy of antitumor
treatment, they failed to improve the appetite or to increase
the weight of cachectic patients (19). Progestational agents
relieve anorexia and reverse weight loss in many patients;
however,theweightgainisaresultoffatratherthanmuscle
accumulation (20).
As epidemiological and experimental studies have
shown that fish oil (rich in n-3 polyunsaturated fatty
acids) has the ability to chemo prevent and to chemo
suppress tumor growth (21–24) via mediating the
production of cytokines such as IL-6 and TNF, normal-
izing the metabolic response in patients with cancer
cachexia, and improving a patient’s nutritional status
(25,26).
Anorexia, defined as the loss of appetite and early
satiety, accounts for the malnutrition that is invariably
associated with cancer cachexia. Host cytokines (TNF-a,
IL-1, and IL-6) are thought to play a key role in cancer-
induced anorexia and to be associated with weight loss
(25–31). This study indicates that ATR might improve
appetite, therefore might partially explain why largehead
atractylodes rhizome can improve appetite in the light of
TCM theory. What’s more, ATR could down-regulate
the serum IL-1 level, and up-regulate serum TNF level.
This might partly explains why ATR has the ability to
improve appetite, and reverse weight loss.
Both humoral (TNF and IL-6) and tumoral factors
(PIF) have been shown to be able to activate the
proteolysis mechanism of skeletal intracellular muscle,
and thus, have a very important role in the induction of
cachexia (31,34). Tumor-derived PIF, a 24-kDa proteo-
glycan (35), is present in a broad spectrum of cancer
patients (i.e. carcinomas of the breast, lung, ovary,
melanoma, gastro intestine). PIF produces direct proteol-
ysis and a direct inhibitory effect on glucose consumption
by skeletal muscle (36). Muscle protein waste is
associated with patient immobility, respiratory dysfunc-
tion, lower immunity and poor performance. It was also
proved that ATR was successful in improving KPS
status, MAMC and decreasing PIF positive rate. These
findings indicate that ATR might have some effects on
muscle metabolism, therefore partially explains why
physical capacity states are ameliorate.
A complex network of cytokines in combination with
other factors may be responsible for the cachexia state of
cancer. None of the mediators alone can fully explain all
the facets of cachectic syndrome (37,38). Therefore, ATR
can up-regulate TNF, down-regulate IL-1, decrease PIF
positive rate and elevate appetite, but it cannot com-
pletely reverse weight loss.
One of the limitations of this study is that since this
was a small unblinded pilot study, and a normal placebo-
treated group was missing in term of ethical concern;
there was potential bias in this study. Therefore it is
necessary to carry out a standard double-blind rando-
mized control trial in future to reassess the favorable
effect of ATR on cancer cachexia and to test the possible
side-effect. Another limitation of this study is that there
was neither direct measurement on the concentration of
ATR in gastric tissue nor on the change of gastric tissue
to ethical concerns after ATR exposure. Instead, the
effects of ATR on gastric cancer cachexia were measured
by the change in biomarkers of serum cytokine levels
such as TNF-a, IL-1, and IL-6 and change in biomarkers
of urine PIF positive rate. Since no definite mediators of
cancer cachexia have yet been identified (37,38) and the
role of cytokines is still quite uncertain, the mechanism of
action by which ATR exerts its beneficial effects is far
from elucidation.
Taken together, our data provide evidence indicating
that the ATR ameliorates the symptoms of gastric cancer
cachexia, most likely through mediation of cytokine
production, and inhibition of PIF proteolysis. These
preliminary findings might aid the development of drugs
to treat cancer cachexia to some extent.
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